Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with two big clinical setbacks. Lundbeck suffered one of the blows: the Danish drugmaker revealed the second and third phase 3 trials of its Alzheimer’s drug had failed, leaving the program without a path to a regulatory filing. The situation at Innate Pharma is less terminal. The French biotech disclosed its Bristol-Myers Squibb-partnered checkpoint inhibitor fell short in a phase 2 acute myeloid leukemia trial. But with combo studies still to come, lirilumab could yet come good. Novo Nordisk backed Denmark’s pitch to host the European Medicines Agency post-Brexit. Merck Serono spinout Prexton Therapeutics raised €29 million ($31 million) to run proof-of-concept Parkinson’s trials. Shares in Targovax jumped on two-year survival data in resected pancreatic cancer. And more.—Nick Taylor
Lundbeck is calling time on development of Alzheimer’s candidate idalopirdine after it chalked up a clean sweep of failures in phase 3. The Danish drugmaker made the decision after learning the 5-HT6 agonist, which failed its first phase 3 in September, had come up short in its second and third late-stage studies.
A phase 2 trial of Innate Pharma’s lirilumab in elderly patients with acute myeloid leukemia (AML) has missed its primary endpoint. The Bristol-Myers Squibb-partnered checkpoint inhibitor failed to improve leukemia-free survival by more than placebo.
Denmark has formally joined the list of countries competing to host the European Medicines Agency (EMA) after Brexit. And the campaign has already enlisted high-profile support, with local success story Novo Nordisk talking up Copenhagen and its ex-CEO Lars Rebien Sorensen signing up as special envoy for the bid.
Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials. The Series B positions the Merck Serono spinout to build on last year’s phase 1 success by testing the mGluR4 positive allosteric modulator in larger efficacy studies.
Targovax has posted two-year survival data from a phase 1/2 trial of TG01 in resected pancreatic cancer patients. More than 60% of participants were alive two years after starting treatment, sparking a 40% surge in the stock price of Targovax.